Heart dosimetric analysis of three types of cardiac toxicity in patients treated on dose-escalation trials for Stage III non-small-cell lung cancer

Kyle Wang, Kevin A. Pearlstein, Nicholas D. Patchett, Allison M. Deal, Panayiotis Mavroidis, Brian C. Jensen, Matthew B. Lipner, Timothy M. Zagar, Yue Wang, Carrie B. Lee, Michael J. Eblan, Julian G. Rosenman, Mark A. Socinski, Thomas E. Stinchcombe, Lawrence B. Marks

Research output: Contribution to journalArticlepeer-review

84 Scopus citations


Background and purpose To assess associations between radiation dose/volume parameters for cardiac subvolumes and different types of cardiac events in patients treated on radiation dose-escalation trials. Material and methods Patients with Stage III non-small-cell lung cancer received dose-escalated radiation (median 74 Gy) using 3D-conformal radiotherapy on six prospective trials from 1996 to 2009. Volumes analyzed included whole heart, left ventricle (LV), right atrium (RA), and left atrium (LA). Cardiac events were divided into three categories: pericardial (symptomatic effusion and pericarditis), ischemia (myocardial infarction and unstable angina), and arrhythmia. Univariable competing risks analysis was used. Results 112 patients were analyzed, with median follow-up 8.8 years for surviving patients. Nine patients had pericardial, seven patients had ischemic, and 12 patients had arrhythmic events. Pericardial events were correlated with whole heart, RA, and LA dose (eg, heart-V30 [p = 0.024], RA-V30 [p = 0.013], and LA-V30 [p = 0.001]), but not LV dose. Ischemic events were correlated with LV and whole heart dose (eg, LV-V30 [p = 0.012], heart-V30 [p = 0.048]). Arrhythmic events showed borderline significant associations with RA, LA, and whole heart dose (eg, RA-V30 [p = 0.082], LA-V30 [p = 0.076], heart-V30 [p = 0.051]). Cardiac events were associated with decreased survival on univariable analysis (p = 0.008, HR 2.09), but only disease progression predicted for decreased survival on multivariable analysis. Conclusions Cardiac events were heterogeneous and associated with distinct heart subvolume doses. These data support the hypothesis of distinct etiologies for different types of radiation-associated cardiotoxicity.

Original languageEnglish (US)
Pages (from-to)293-300
Number of pages8
JournalRadiotherapy and Oncology
Issue number2
StatePublished - Nov 2017
Externally publishedYes


  • Cardiac toxicity
  • Chemoradiation
  • Dose escalation

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Radiology Nuclear Medicine and imaging


Dive into the research topics of 'Heart dosimetric analysis of three types of cardiac toxicity in patients treated on dose-escalation trials for Stage III non-small-cell lung cancer'. Together they form a unique fingerprint.

Cite this